GeneDx Holdings/$WGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GeneDx Holdings
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Ticker
$WGS
Sector
Primary listing
Industry
Health Care Providers and Services
Headquarters
Employees
1,000
Website
GeneDx Holdings Metrics
BasicAdvanced
$3B
2,135.86
$0.05
2.08
-
Price and volume
Market cap
$3B
Beta
2.08
52-week high
$117.75
52-week low
$25.32
Average daily volume
1M
Financial strength
Current ratio
2.869
Quick ratio
2.557
Long term debt to equity
40.162
Total debt to equity
41.274
Interest coverage (TTM)
2.40%
Profitability
EBITDA (TTM)
29.643
Gross margin (TTM)
67.20%
Net profit margin (TTM)
0.39%
Operating margin (TTM)
1.98%
Effective tax rate (TTM)
8.46%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
1.05%
Return on equity (TTM)
0.60%
Valuation
Price to earnings (TTM)
2,135.856
Price to revenue (TTM)
7.972
Price to book
10.72
Price to tangible book (TTM)
33.95
Price to free cash flow (TTM)
3,479.913
Free cash flow yield (TTM)
0.03%
Free cash flow per share (TTM)
0.03
Growth
Revenue change (TTM)
48.70%
Earnings per share change (TTM)
-101.08%
3-year revenue growth (CAGR)
23.77%
3-year earnings per share growth (CAGR)
-87.02%
Bulls say / Bears say
GeneDx Holdings reported a 64% year-over-year increase in fourth-quarter 2024 revenues, reaching $95.3 million, indicating strong financial growth. (genedx.com)
The company achieved an adjusted gross margin of 70% in Q4 2024, up from 56% in the same quarter of the previous year, reflecting improved operational efficiency. (genedx.com)
Jefferies upgraded GeneDx Holdings' stock rating from 'Hold' to 'Buy' in May 2025, suggesting increased confidence in the company's future performance. (nasdaq.com)
Despite revenue growth, GeneDx Holdings reported a net loss of $6.5 million in Q1 2025, indicating ongoing profitability challenges. (gurufocus.com)
The company relies on third-party service providers for components of its diagnostic testing workflows, which could pose risks related to supply chain disruptions and quality control. (gurufocus.com)
GeneDx operates in a highly competitive genomics industry, facing challenges from numerous players, which could impact its market share and pricing power. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
GeneDx Holdings News
AllArticlesVideos
GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options
CNBC Television·1 day ago
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
Business Wire·2 days ago
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
MarketBeat·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GeneDx Holdings stock?
GeneDx Holdings (WGS) has a market cap of $3B as of July 31, 2025.
What is the P/E ratio for GeneDx Holdings stock?
The price to earnings (P/E) ratio for GeneDx Holdings (WGS) stock is 2135.86 as of July 31, 2025.
Does GeneDx Holdings stock pay dividends?
No, GeneDx Holdings (WGS) stock does not pay dividends to its shareholders as of July 31, 2025.
When is the next GeneDx Holdings dividend payment date?
GeneDx Holdings (WGS) stock does not pay dividends to its shareholders.
What is the beta indicator for GeneDx Holdings?
GeneDx Holdings (WGS) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.